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BACKGROUND: Neuroblastoma (NB) is the most common extra-cranial solid tumour in infants. Unfortunately, most children present
with advanced disease and have a poor prognosis. There is in vitro evidence that the peroxisome proliferator-activated receptor g
(PPARg) might be a target for pharmacological intervention in NB. We have previously demonstrated that the PPARg agonist
rosiglitazone (RGZ) exerts strong anti-tumoural effects in the human NB cell line, SK-N-AS. The aim of this study was to evaluate
whether RGZ maintains its anti-tumoural effects against SK-N-AS NB cells in vivo.
METHODS AND RESULTS: For this purpose, tumour cells were subcutaneously implanted in nude mice, and RGZ (150mgkg
 1) was
administered by gavage daily for 4 weeks. At the end of treatment, a significant tumour weight inhibition (70%) was observed in
RGZ-treated mice compared with control mice. The inhibition of tumour growth was supported by a strong anti-angiogenic activity,
as assessed by CD-31 immunostaining in tumour samples. The number of apoptotic cells, as determined by cleaved caspase-3
immunostaining, seemed lower in RGZ-treated animals at the end of the treatment period than in control mice, likely because of the
large tumour size observed in the latter group.
CONCLUSIONS:To our knowledge, this is the first demonstration that RGZ effectively inhibits tumour growth in a human NB xenograft
and our results suggest that PPARg agonists may have a role in anti-tumoural strategies against NB.
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Neuroblastoma (NB) is a neoplastic disease of the sympathetic
nervous system, derived from neuronal crest cells, and represents
the second most common extra-cranial tumour in childhood
and accounts for more than 7% of malignancies in patients
younger than 15 years (National Cancer Institute, Surveillance,
Epidemiology and End Results Database, 2005). Neuroblastoma is
characterised by a heterogeneous clinical presentation and course
(Maris et al, 2007), but the prognosis is often severe (around 15%
of all paediatric oncology deaths) (Joshi and Tsongalis, 1997). In
fact, most children with NB present with advanced disease and
metastases at diagnosis and, despite intensive therapy, at least 60%
of patients with high-risk features have a poor prognosis and high
relapse chance (Matthay et al, 1999; De Bernardi et al, 2003). Thus,
the identification of new and more effective therapies would be of
pivotal importance to improve the outcome of affected children.
Retinoids have been shown for instance to interfere with cell
growth and to induce apoptosis in NB cells (Melino et al, 1997;
Voigt and Zintl, 2003), and in clinical trials they effectively
increase event-free survival in high-risk patients, with limited toxic
effects (Garaventa et al, 2003; Reynolds et al, 2003). Thiazolidi-
nediones (TZDs), a class of molecules that activate the nuclear
receptor peroxisome proliferator-activated receptor g (PPARg)
(Desvergne and Whali, 1999), promote association with the 9-cis
retinoic X receptor to form functional heterodimers that recognise
specific DNA response elements within target genes (Jude-Aubry
et al, 1997; Reginato et al, 1998). The PPARg, initially described in
adipose tissue (Tontonoz et al, 1993), is classically related to
adipocyte turnover (Spiegelman, 1998), glucose and lipid metabo-
lism regulation (Saltiel and Olefsky, 1996; Koeffler, 2003). In
addition, a role of PPARg against inflammation, atherosclerosis
and tumoural growth has been described (Jiang et al, 1998; Ricote
et al, 1998; Kersten et al, 2000). In particular, PPARg signalling
activation inhibits cell proliferation and/or induces apoptosis
(Grommes et al, 2004). As a consequence, PPARg has been
regarded as a possible target for anti-cancer therapy and TZDs
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shave been used in clinical trials for the treatment of tumours
involving different organs and tissues, such as prostate (Hisatake
et al, 2000; Mueller et al, 2000), colon (Kulke et al, 2002), breast
(Burstein et al, 2003), lung and adipose tissue (Demetri et al, 1999;
Tsubouchi et al, 2000; Debrock et al, 2003).
Abundant PPARg expression has been detected in different
tumours affecting the nervous system, such as astrocytomas
(Chattopadhyay et al, 2000), gliobastomas (Nwankwo and
Robbins, 2001; Morosetti et al, 2004) and NB (Han et al, 2001).
In the recent past, it has been observed that in different NB cell
lines expressing PPARg, endogenous or synthetic ligands induce
anti-neoplastic effects such as cell differentiation, apoptosis,
growth arrest, reduced viability and inhibition of invasiveness
(Emmans et al, 2004; Servidei et al, 2004; Valentiner et al, 2005;
Cellai et al, 2006; Peri et al, 2008).
In particular, we have previously shown that PPARg agonist
rosiglitazone (RGZ) exerts strong anti-neoplastic effects (i.e.,
inhibition of cell proliferation and cell viability, decrease of matrix
metalloproteinase-9 (MMP-9) expression, inhibition of cell adhe-
sion and invasiveness) in SK-N-AS but not in SH-SY5Y human NB
cells (Cellai et al, 2006). We also demonstrated that the different
efficacy of RGZ was related to the presence of a significantly higher
transcriptional activity of PPARg in SK-N-AS compared with
SH-SY5Y, which was most likely because of a markedly higher
amount of phosphorylated, that is, inactive, PPARg in the latter cell
line. The aim of this study was to evaluate whether RGZ maintains
its anti-tumoural effects against SK-N-AS NB cells in vivo. For this
purpose, tumour cells were subcutaneously implanted in nude
mice, and the effects of RGZ treatment against tumour growth,
angiogenic activity and apoptosis induction were investigated.
MATERIALS AND METHODS
In vivo studies
Rosiglitazone maleate was provided by Vinci Biochem, Vinci, Italy.
For in vivo studies, RGZ was dissolved in glycine/HCl buffer
at pH 2.3, at a concentration of 7.5mgml
 1. Anti-tumour activity
experiments were carried out using 8–11-week-old female
athymic Swiss nude mice (Charles River, Calco, Italy). Mice were
maintained in laminar flow rooms with constant temperature and
humidity. Experimental protocols were approved by the Ethics
Committee for Animal Experimentation of the Fondazione IRCCS
Istituto Nazionale Tumori (Milan, Italy), according to the United
Kingdom Coordinating Committee on Cancer Research Guidelines
(Workman et al, 1988).
Human NB SK-N-AS was maintained in vivo by serial sub-
cutaneous passages of tumour fragments (about 2 2 6mm) in
healthy mice, as previously described (Pratesi et al, 1985).
For anti-tumour activity studies, each experimental group (i.e.,
solvent treated or RGZ treated) included 16 mice bearing a
subcutaneous tumour in the right flank. Tumour fragments were
implanted on day 1 and tumour growth was followed by bi-weekly
measurements of tumour diameters using a Vernier caliper.
Tumour weight (TW) was calculated according to the formula
TW (mg)¼tumour volume (mm
3)¼d
2 D/2, where d and D
are the shortest and the longest diameters, respectively. Drug
treatment started at day 1, shortly after tumour implant. RZG was
delivered p.o. by gavage in a volume of 20mlkg
 1 of body weight,
at a dose of 150mgkg
 1 according to a daily schedule (weekend
excluded) for 4 weeks, for a total of 20 treatments. Control mice
were treated in parallel with glycine/HCl buffer. Rosiglitazone
treatment was stopped after 4 weeks; at this time, control tumours
had reached about 2g of weight, which is considered the maximum
tolerated for ethical reasons. Drug efficacy was assessed as tumour
weight inhibition % (TWI%)¼100–(mean TW RGZ-treated mice/
mean TW control mice 100), evaluated during and after drug
treatment. Drug tolerability was assessed in tumour-bearing mice
in terms of (a) lethal toxicity, that is, any death in RGZ-treated
mice occurring before any death in control mice; (b) body weight
loss percentage¼100–(body weight on day x/body weight on day
1 100), where x represents a day after or during the treatment
period. Experimental groups were killed by cervical dislocation the
day after the last treatment (day 26). Half of RGZ-treated and
control mice were killed after 2 weeks for immunohistochemical or
gene expression analyses (as detailed below).
Immunohistochemical studies
After killing the mice, tumours were excised. Half of each
tumour was fixed in 10% buffered formalin and the other
half in zinc fixative. Samples were fixed for 24h, embedded in
paraffin, sectioned at 4mm and stained with standard haema-
toxylin and eosin or processed for immunohistochemical
analysis. For caspase-3 and CD31 immunohistochemistry, sections
were deparaffinised, rehydrated and treated with 3% hydrogen
peroxide in distilled water for 20min. The sections were labelled
by the avidin–biotin–peroxidase procedure (Hsu et al, 1981)
with a commercial immunoperoxidase kit (Vectastain Standard
Elite; Vector Laboratories, Burlingame, CA, USA). Primary
antibodies were applied at 41C overnight. The reaction was
revealed by incubating the sections with 3,3 diaminobenzidine
(Vector Laboratories) for 1min; the sections were counterstained
for 1min with Mayer’s haematoxylin. Rabbit polyclonal
anti-cleaved caspase-3 (Asp175) antibody (Cell Signaling Techno-
logy, #9661, Danvers, MA, USA) was applied on formalin-fixed
sections at a working dilution of 1:2500. For cleaved caspase-3
evaluation, four hot spots of each sample were randomly selected
at  100 magnification and the number of cleaved caspase-3-
positive cells was assessed in a  400 microscopic field within
each hot spot. All the hot spots selected were distributed
along the interface between viable tumoural structures and
necrotic areas.
To establish microvessel density, zinc-fixed sections from each
tumour were immunostained with the rat monoclonal anti-mouse
CD-31 antibody, MEC 13.3 (PharMingen, San Diego, CA, USA),
a specific marker for endothelial cells (Vecchi et al, 1994), applied
at a working dilution of 1:50. For each sample, CD-31-positive
microvessels were counted in four  100 microscopic fields
randomly selected within viable tumoural areas.
For the immunohistochemical evaluation of Ki-67 expression,
tumour samples fixed in buffered formalin were cut into 5-mm-
thick sections. Next, the sections were deparaffinised in xylol for
30min, rehydrated in ethanol and washed in buffered saline
solution (phosphate-buffered saline) at pH 7.4. For antigen
recovery, slides were placed in racks containing 10mM citric acid
(pH 6.0) and heated in a microwave oven for 25min at maximum
power. The slides were then allowed to cool for 15min in water
and washed in phosphate-buffered saline. Subsequently, the
sections were treated for 5min with peroxidase block reagent
(Dako, Glostrup, Denmark) to block endogenous peroxidases.
Incubation with primary mouse anti-Ki-67 monoclonal antibody
(clone MIB1, Dako) for 1h (dilution 1:50) preceded the
application of the avidin–biotin system ENVISIONþ system-
HRP (Dako) and visualisation was performed using 3,3 diamino-
benzidine (Dako) as chromogen. Finally, the slides were washed
with distilled water, counterstained with haematoxylin, dehydrated
with ethanol and mounted with coverslips. Cells that expressed the
Ki-67 protein were identified by the dark brown colouring of
the nucleus. For each sample, Ki-67-positive cells were counted in
eight  200 microscopic fields randomly selected within viable
tumoural areas.
The image analysis of each immunostaining was performed
using Image-Pro Plus Software (Bethesda, MD, USA).
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sQuantitative real-time reverse transcriptase PCR
Total RNA to be subjected to reverse transcription was extracted
from tumour specimens. Total RNA isolation and cDNA synthesis
were performed as previously reported (Luciani et al, 2004).
Primers and probe for PPARg was Assay-On-Demand gene
expression products (Hs00234592_m1; Applied Biosystems, Foster
C i t y ,C A ,U S A ) .P C Rm i x t u r e( 2 5 ml final volume) consisted of 1 
final concentration of Assay-On-Demand mix, 1  final concentration
of Universal PCR Master Mix (Applied Biosystems) and 20ng cDNA.
Measurement of MMP-9 and tissue inhibitor of matrix
metalloproteinase-1 (TIMP-1) mRNA was performed using a
multiplex quantitative real-time reverse transcriptase PCR method,
using primers and probes as previously described (Cioppi et al,
2004). Each measurement was carried out in triplicate. According
to the manufacturer’s instructions (Applied Biosystems), PPARg
mRNA quantitation was based on the comparative cycle threshold
(Ct) method using ribosomal 18S RNA expression for normal-
isation. The results were expressed as (2
 DDCt) 10
3.
Western blot analysis of PPARc expression
The PPARg expression was determined as previously described
(Cellai et al, 2006). Briefly, tissue samples were dissolved in lysis
buffer. A volume of 30mg of protein was diluted in 2  Laemmli’s
reducing sample buffer, incubated at 951C for 5min and loaded
onto a 10% polyacrylamide–bisacrylamide gel. Thereafter,
proteins were electroblotted into nitrocellulose (Sigma Co.,
St. Louis, MO, USA). Equivalent protein loading was verified by
staining parallel gels with Coomassie R and by using tubulin as a
reference protein. After blocking (5% skimmed milk for 2h),
nitrocellulose membranes were washed and then immunostained
with a rabbit anti-human PPARg antibody (1:1000) (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) or with an anti-phospho-
PPARg (Ser82) clone AW 504 (1:1000) (Upstate, Lake Placid, NY,
USA), followed by a secondary anti-rabbit IgG antibody (1:2000)
(New England Biolabs, Beverly, MA, USA). The antibody-reacted
proteins were revealed by LumiGLO chemiluminescent reagent
and peroxide (New England Biolabs).
PPARc phosphorylation assay
The assay was performed as previously described (Cellai et al,
2006). Briefly, tissue samples were boiled and dissolved in 10%
glycerol, 2% SDS, and 50mM Tris–HCl (pH 7.5) for 10min. The
lysate was immunoprecipitated with a rabbit anti-human PPARg
antibody (1:100) (Santa Cruz Biotechnology) at 41C for 3h.
Immunocomplexes were recovered by incubation with Protein-A
Sepharose (Sigma Co.) for an additional 16h at 41C. The
immunocomplexes were then dissociated by boiling for 5min in
Laemmli’s buffer, the beads were collected by centrifugation and
SDS–polyacrylamide gel electrophoresis was performed with the
supernatant. The proteins were electroblotted into nitrocellulose
transfer membrane Protean (Whatman, VWR International, Milan,
Italy) and were detected by incubating the filter with the anti-
PPAR-g antibody or with an anti-phosphoserine mouse mono-
clonal antibody (1:400) (clone PSR-45, Sigma Co.) followed by a
secondary anti-rabbit IgG (1:2000) or anti-mouse IgG (1:2000)
antibody, respectively (Amersham Biosciences, Little Chalfont,
Buckinghamshire, UK). To verify equivalent protein loading,
tubulin was chosen as the reference protein. Detection of the
protein bands was performed using the Amersham ECL plus Kit
(Amersham Biosciences).
Statistical analysis
Data from anti-tumour activity studies were analysed using two-
way analysis of variance, followed by post hoc Bonferroni test.
Differences in immunohistochemistry studies were compared by
Student’s t-test (two tailed). The Spearman’s rank correlation
analysis was used to determine the relationship between TW
and cleaved caspase-3 immunopositive cells. P-values o0.05 were
considered as statistically significant. Analyses were performed
with Graph Pad Prism, version 4.0 (Graph Pad Software Inc., San
Diego, CA, USA).
RESULTS
Effect of RGZ on tumour growth
For anti-tumour activity studies, RGZ was delivered p.o. by gavage
at a dose of 150mgkg
 1 daily (weekend excluded) for 4 weeks
against the SK-N-AS human NB tumour xenograft. The drug was
well tolerated without lethal toxicity and body weight loss during
treatment (Figure 1). Plasma glucose levels did not significantly
differ at baseline or at the end of treatment (4 weeks) (88±7.73 vs
104.75±2.93mg per 100ml, mean±s.e., respectively, P40.05).
At the end of RGZ treatment, a marked TW inhibition (70%) was
observed, compared with control mice (TW 670±214 vs
2250±300mg, mean±s.e., respectively, Po0.005, Figure 2 and
Table 1). Moreover, in the RGZ-treated group, three out of eight
tumours were very small (o50mg). These mice were not killed
immediately after the end of RGZ administration and were
subjected to an additional follow-up. One of the three tumours
did not re-grow for up to 100 days (when the mouse was killed),
and for the other two tumours, re-growth was observed 2 weeks
after the end of treatment.
Effect of RGZ on apoptosis and proliferation
To investigate the cellular mechanisms underlying RGZ activity,
growing tumours from control and RGZ-treated mice were
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Figure 1 Mean body weight of mice during the treatment period. (A) Solvent-treated mice; (B) rosiglitazone (RGZ)-treated mice.
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of the tumours/group) and 4 weeks of treatment. Histologically,
by standard haematoxylin and eosin staining, control and
RGZ-treated tumours seemed to be composed of sheets of dense
to sparsely packed cells divided by septa of fibrovascular
stroma. Peritumoural lymphoplasmacytic infiltrates were present
(not shown).
With regard to apoptosis, at short-time observation (2 weeks),
that is, in the presence of small-sized tumours, a low number of
apoptotic cells was present, but in mice treated with RGZ, the
number of cleaved caspase-3 immunopositive cells was higher than
in controls, although the difference was not statistically significant
(P¼0.12) (Table 1 and Figure 3A). At such a time, necrosis was
virtually absent in RGZ-treated tumours and rare and very limited
necrotic areas were present in control tumours. A different pattern
was observed in samples from mice killed after 4 weeks of
treatment, in which, in large-sized control tumours (mean
TW42g), large necrotic areas and a high number of apoptotic
cells were observed. At such a time, in RGZ-treated tumours, the
number of caspase-3 immunopositive cells was significantly lower
(Po0.05) and necrotic areas were less extended than in solvent-
treated tumours (Table 1 and Figure 3B). Figure 4 shows that, in
control mice, a linear relation (R¼0.835, Po0.05, by Spearman’s
rank correlation test) between positive staining for cleaved
caspase-3 and tumour size was found. These results indicate that
at the 2-week observation time, RGZ treatment increases the
apoptotic index, whereas at 4 weeks, necrosis and apoptotic index
are likely to be related to tumour size. Nevertheless, if we compare
Table 1 Anti-tumour effects of oral rosiglitazone maleate delivered daily against the SK-N-AS human neuroblastoma xenograft.
Number of apoptotic cells
b (mean value±s.e.) MVD
c (mean value±s.e.)
Drug Dose (mgkg
 1) TWI%
a 2w
d 4w
d 2w
d 4w
d
Solvent
e —— 9 ±24 8 ±71 0 ±11 7 ±2
Rosiglitazone 150 701 14±22 8 ±7* 7±15 ±2**
aTWI%¼tumour weight inhibition percentage in rosiglitazone-treated vs control mice. TWI% was calculated 1 day after the last treatment (4 weeks after tumour inoculum).
bMean number of apoptotic (caspase-3+) cells per field ±s.e. ( 400 magnification).
cMVD¼microvessel density. MVD¼mean number of CD31
+ cells per field ±s.e. ( 400
magnification).
d2wand4w¼2 weeks and 4 weeks after the beginning of treatment.
eSolvent¼glycine/HCl buffer at pH 2.3. 1Po0.005 vs controls, by analysis of variance
followed by Bonferroni test. *Po0.05 and **Po0.005 vs controls, by Student’s t-test (two-tailed).
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Figure 2 Growth curves of the SK-N-AS neuroblastoma (NB)
xenograft. Tumour weight over time in solvent-treated (open circles)
and 150mgkg
 1 rosiglitazone (RGZ)-treated (filled circles) mice. Treat-
ments were delivered daily, by gavage, for 4 weeks (except weekend).
Arrows indicate the first and last day of treatment. Each point represents
the average±s.e. of at least eight tumours. *Po0.005 and
#Po0.01
(solvent-treated vs RGZ-treated mice) by analysis of variance, followed by
Bonferroni test.
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Figure 3 Immunohistochemistry (IHC) for cleaved caspase-3 assess-
ment in tumour tissues from control (i.e., solvent treated) and rosiglitazone
(RGZ)-treated (A, 2 weeks; B, 4 weeks) mice. Y axis: number of cleaved
caspase-3-positive cells per field.
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Figure 4 Relationship between tumour weight and cleaved caspase-3
immunopositive cells in SK-N-AS neuroblastoma xenografts. Black squares indicate
solvent-treated tumours. R¼0.835, Po0.05, by Spearman’s rank correlation test.
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solvent-treated or RGZ-treated mice, we can observe that when in
both groups the TW reached 670g (i.e., the mean weight of tumours
in RGZ-treated mice at the end of treatment, approximately
corresponding to the weight of tumours in control mice after 2
weeks), the mean percentage of apoptotic cells was 10% in control
mice, whereas it reached 30% in RGZ-treated mice (Figures 2 and 3).
The proliferation rate of tumoural cells was also assessed, by
determining the immunostaining for the Ki-67 index. After 2
weeks, the mean percentage of Ki-67-positive cells was moderately
lower in RGZ-treated mice than in control mice (1.92±0.07 vs
2.17±0.29, mean±s.e., P¼0.44). Such a difference, yet non-
statistically significant, was maintained also at the end of the
treatment period (4 weeks) (1.6±0.27 vs 2.25±0.43, mean±s.e.,
P¼0.26). A representative example is shown in Figure 5. It has to
be said that the same above-mentioned observations regarding the
extension of necrotic areas at the end of the treatment period,
particularly in tumours of control mice, may also very likely be
applicable in explaining the absence of a more pronounced
difference of the percentage of Ki-67-positive cells between the two
groups of animals.
Effect of RGZ on angiogenesis
In the same tumour samples used for apoptosis assessment,
tumour angiogenesis was investigated by determining the percen-
tage of cells showing a positive staining for CD-31. The number
of immunopositive cells seemed reduced (yet not significantly,
P¼0.058) after 2 weeks of RGZ treatment (Table 1 and Figure 6A).
In tumours of mice treated with RGZ for 4 weeks, the reduction in
CD-31-positive cells became statistically significant (Po0.005)
(Table 1 and Figure 6B). A large variability among the different
tumour samples of RGZ-treated mice was observed, and a strong
inhibitory effect could be observed in some of them (Figures 6C–D).
PPARc expression
To determine whether RGZ treatment affected the expression of
PPARg, both mRNA and protein levels were evaluated. The PPARg
transcript, as assessed by quantitative real-time reverse transcriptase
PCR, did not significantly differ in tumours from control or RGZ-
treated (4 weeks) mice (Table 2). Similarly, the amount of PPARg
protein, detected by western blot analysis, was not different in the
two groups. Because there is evidence that PPARg phosphorylation
reduces the activity of the receptor (Shao et al, 1998), western blot
analysis was performed using an anti-phosphoserinel antibody as
well. Moreover, the amount of phosphorylated, hence inactivated,
PPARg was virtually equal in tumours from RGZ-treated and
control mice (Table 2). A representative example of PPARg and
Control
CD-31 (4 weeks)
Control RGZ-treated
0
10
20
30
40
CD-31 (2 weeks)
Control RGZ-treated
0
10
20
30
RGZ-treated
Figure 6 Immunohistochemistry (IHC) for CD-31 evaluation in tumour tissues from control (i.e., solvent treated) and rosiglitazone (RGZ)-treated (A,2
weeks; B, 4 weeks) mice. Y axis: number of CD-31-positive cells per field. (C) Example of a field showing high CD-31 staining in the tissue sample from a
control mouse. (D) Example of a field showing a few CD-31-positive cells after 4 weeks of treatment with RGZ ( 100 magnification).
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Figure 5 Immunohistochemical evaluation of Ki-67 in tumours from
solvent-treated and rosiglitazone (RGZ)-treated mice (2, A–B, and 4,
C–D, weeks) ( 200 magnification). Necrotic areas are present on the
right-end side of C and, to a much lesser extent, in D.
Table 2 PPARg expression in RGZ-treated or solvent-treated mice
Solvent RGZ
PPARg (mRNA expression)
a 4.91±1.12 2.295±0.815
PPARg (total protein amount)
b 193.15±1.53 192.82±4.44
P-PPARg (protein amount)
b 167.495±20.60 175.125±18.92
Abbreviations: PPARg¼peroxisome proliferator-activated receptor g; P-PPARg¼-
phosphorylated PPARg;R G Z ¼rosiglitazone.
a(2
 DDCt) 10
3.
bArbitrary units (as
assessed by densitometry).
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treated mice is shown in Figure 7.
MMP-9 and TIMP-1 expression
We demonstrated previously that RGZ determines a significant
reduction in MMP-9 and a trend towards an increase in TIMP-1
expression in SK-N-AS cells (Cellai et al, 2006). In this study, we
were able to determine the amount of mRNA of MMP-9 and TIMP-
1 in the few residual tumour tissues that were available (n¼3 for
each group, i.e., RGZ-treated (4 weeks) or control mice). Owing to
the limited number of samples and the variability of data in each
group, a statistical analysis could not be performed. However, the
median of the amount of MMP-9 mRNA seemed to be reduced
in RGZ-treated mice compared with control animals (0.83 vs 0.94
(2
 DDCt) 10
3, respectively), whereas the expression of TIMP-1
showed an opposite trend (3.78 vs 2.13 (2
 DDCt) 10
3, respectively).
DISCUSSION
We demonstrated previously that RGZ exerts anti-neoplastic
effects in SK-N-AS NB cells in which a transcriptionally active
PPARg is present. In this new study, we evaluated the effect of RGZ
against SK-N-AS cells xenografted in vivo. Rosiglitazone was
administered for 4 weeks at a dose of 150mgkg
 1day
 1,i n
agreement with previously published data, reporting doses ranging
from 120 to 150mgkg
 1 daily (Heaney et al, 2002; Bogazzi et al,
2004). According to the low toxicity profile shown by RGZ as an
anti-diabetic agent (Yki-Ja ¨rvinen, 2004), RGZ was well tolerated in
our study and no body weight loss or lethal toxicity was observed
during the treatment. At the end of the scheduled time for RGZ
administration, no difference in plasma glucose levels was
detected, suggesting that RGZ may be administered in non-
diabetic subjects without undesirable effects on glucose metabo-
lism. With regard to tumour growth, a significant difference
between the TW of RGZ-treated and control mice was observed
(TWI¼70%). It is noteworthy that three out of eight tumours
grown in mice exposed to RGZ weighed o50mg at the end of
treatment. These animals were monitored for an additional period
of time. In two cases, tumour re-growth was observed only 2 weeks
after the end of treatment, and in one case, the tumour never
started to re-grow. Therefore, in about 40% of mice, RGZ
administration determined a virtually complete inhibitory effect
on NB growth that lasted, at least partially, even after the cessation
of treatment. Thus, this PPARg agonist proved to effectively inhibit
the growth of an NB tumour xenograft, in keeping with similar
findings obtained using PPARg agonists against other types of
tumour xenografts, such as colorectal (Katoh et al, 2004;
Yoshizumi et al, 2004; Cesario et al, 2006; Shimazaki et al, 2008),
lung (Nemenoff, 2007; Hazra et al, 2008; Roman, 2008), prostate
(Annicotte et al, 2006), bladder and ovarian cancer (Kassouf et al,
2006; Xin et al, 2007).
To elucidate the mechanism(s) by which RGZ exerted an
inhibitory effect on tumour growth, tissue samples were obtained
from killed RGZ-treated and control mice after 2 and 4 weeks of
treatment. After 2 weeks, in tumours excised from animals treated
with RGZ, the number of apoptotic cells seemed to be increased,
although the difference was not statistically significant. This result
is in agreement with our previous in vitro observations on SK-N-
AS cells exposed to RGZ (Cellai et al, 2006), as well as with other
similar reports on the pro-apoptotic effects of PPARg agonists in
different NB cell lines (Rohn et al, 2001; Kato et al, 2002; Kim et al,
2003; Schultze et al, 2006). The PPARg agonists-induced apoptosis
has been described as a surveillance mechanism against tumour
growth and invasion in NB (Grommes et al, 2004; Stupack et al,
2006). Conversely, at the end of treatment, the number of apoptotic
cells was significantly higher in tumours from control mice, most
likely because of the presence of large expanding masses of about
2g in these tumours. Accordingly, we observed a direct relation-
ship between TW and apoptotic cells in tumours grown in solvent-
treated mice. The finding of a high percentage of apoptotic cells in
growing lesions is a known phenomenon that has been described
in tumours of different tissues, such as the breast (Vakkala et al,
1999; Wong et al, 2001; O’Donovan et al, 2003) and the adrenal
gland (Bernini et al, 2002; Stojadinovic et al, 2003; Luciani et al,
2004). Anyway, when we compared the rate of apoptosis in tumour
samples of the same size from solvent-treated or RGZ-treated
mice, we observed a markedly higher percentage of apoptotic cells
in the latter group, thus confirming that a pro-apoptotic effect of
RGZ on NB cells occurs in vivo as well. We also observed a
moderately reduced percentage of Ki-67-positive NB cells in RGZ-
treated mice vs control mice, both after 2 and 4 weeks of treatment.
Also, in this case, the presence of large volume tumours with
extended necrotic areas in control animals at the end of the treatment
period may likely justify the absence of a greater difference in the
proliferation rate between the two groups of animals.
Similar to many other tumours, the progression of NB is
associated with the activity of MMPs that promote the invasion of
the extra-cellular matrix by tumoural cells and trigger angiogenesis
by different modalities, such as the release of vascular endothelial
growth factor, the recruitment of pericytes along endothelial cells
and the mobilisation of haematopoietic stem cells into circulation
(Sugiura et al, 1998; Bergers et al, 2000; Heissig et al, 2002;
Chantrain et al, 2004). We previously demonstrated the efficacy of
RGZ in inhibiting in vitro SK-N-AS cell invasiveness through a
significant reduction in the expression of MMP-9 (Cellai et al,
2006). In this study, we have shown that RGZ determines a marked
anti-angiogenic effect in vivo, as assessed by the significant
reduction in the number of CD-31 immunopositive cells. In
addition, in residual tumour samples, the amount of MMP-9
mRNA seemed to be reduced at the end of RGZ treatment
compared with that in the control group, whereas an opposite
trend was observed for TIMP-1 expression. It has to be said that
data on MMP-9 and TIMP-1 expression were obtained from a
limited sample size and it was not possible to perform a statistical
analysis. Nevertheless, these observations seem to be in agreement
with the observed anti-angiogenic effect of RGZ in vivo and may be
responsible, at least partially, for such an effect.
Finally, we demonstrated that neither the expression of PPARg
nor the expression of the inactivated form of the receptor, that is,
phosphorylated PPARg, were significantly different in tumours
from RGZ-treated and solvent-treated mice, thus suggesting that
the binding capacity of this molecule to its receptor was
maintained throughout the entire treatment period. However, we
cannot exclude the fact that the anti-neoplastic effects of RGZ
were, at least in part, PPARg independent. Previous in vitro and in
vivo evidence suggests that the anti-proliferative effect of TZD is
independent of PPARg transcriptional activity (Galli et al, 2006).
Tubulin -
PPAR -
P-PPAR -
Control RGZ
Figure 7 Western blot analysis of the amount of peroxisome
proliferator-activated receptor g (PPARg) and phosphorylated PPARg
(P-PPARg) in rosiglitazone (RGZ)-treated and solvent-treated mice.
Tubulin amount was determined to verify equivalent protein loading.
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by inhibition of translation initiation in PPARg
 /  embryonic
stem cells. Furthermore, TZD analogues, which have a double
bond adjoining the terminal TZD ring that is responsible for the
abrogation of the PPARg ligand property, retain the ability to
induce apoptosis in prostate cancer cells (Weng et al, 2006).
In conclusion, in this study, we demonstrated that the PPARg
agonist RGZ effectively inhibits tumour growth in a human NB
xenograft. This anti-tumoural effect seemed to be mostly due to a
strong anti-angiogenic activity. To our knowledge, this is the first
demonstration that PPARg agonists may be effective against NB
in vivo, thus suggesting the interest for clinical studies. It has to be
said that SK-N-AS cells were selected for this study on the basis of
the presence of a high transactivation potential of PPARg, which
was related to low levels of phosphorylated PPARg (Luciani et al, 2004).
Thus, in designing clinical trials, it might be useful to preliminarily
determine the ratio between total and phosphorylated PPARg in tissue
specimens to select hypothetically responsive patients.
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